PMID- 35647858
OWN - NLM
STAT- MEDLINE
DCOM- 20220603
LR  - 20220804
IS  - 2284-0729 (Electronic)
IS  - 1128-3602 (Linking)
VI  - 26
IP  - 10
DP  - 2022 May
TI  - Pulmonary embolism in patients with dyspnea after COVID-19 infection.
PG  - 3751-3759
LID - 28872 [pii]
LID - 10.26355/eurrev_202205_28872 [doi]
AB  - OBJECTIVE: Pulmonary embolism as a potential complication that may occur late in 
      the course of COVID-19 cases. The aim of our study is to evaluate the frequency 
      of pulmonary embolism in patients with new or ongoing dyspnea after a COVID-19 
      infection. PATIENTS AND METHODS: This is a single-center, prospective 
      observational study to evaluate the clinical and radiological outcomes of 
      consecutive patients presenting outpatient clinic diseases to the chest and a new 
      or ongoing dyspnea after a COVID-19 infection. Demographic, clinical and 
      laboratory data were collected. Dyspnea was evaluated according to the New York 
      Heart Association (NYHA) classification. RESULTS: Pulmonary embolism was detected 
      in 23.8% (25/105) of patients with new or ongoing dyspnea after a COVID-19 
      infection. Proportion of pulmonary embolism in patients with NYHA classes I, II, 
      III and IV were respectively 8.7%, 20.0%, 30.0% and 35.3% (p for trend=0.02). 
      Compared to NYHA class I and II patients with dyspnea, those in NYHA classes III 
      and IV showed a higher rate of pulmonary embolism [31.6% vs. 14.6%, OR: 2.7 (1.0 
      to 7.1), p=0.04, respectively]. In Logistic Procedures, NYHA classes of dyspnea 
      (OR: 4.3, 95% CI: 1.2 to 16.6, p=0.03) (NYHA class III and IV vs. NYHA class I 
      and II) determine the likelihood of pulmonary embolism after COVID-19 infection. 
      CONCLUSIONS: Pulmonary embolism is common in patients with new or ongoing 
      shortness of breath after a COVID-19 infection. Pulmonary embolism is more likely 
      to develop in patients with higher NYHA classes.
FAU - Ekici, A
AU  - Ekici A
AD  - Department of Chest Diseases, Kirikkale University Faculty of Medicine, Yahsihan, 
      Kirikkale, Turkey. mehmetekici_@hotmail.com.
FAU - Ekici, M
AU  - Ekici M
FAU - Baccioglu, A
AU  - Baccioglu A
FAU - Akyuz Inanc, F
AU  - Akyuz Inanc F
FAU - Aslan, H
AU  - Aslan H
LA  - eng
PT  - Journal Article
PT  - Observational Study
PL  - Italy
TA  - Eur Rev Med Pharmacol Sci
JT  - European review for medical and pharmacological sciences
JID - 9717360
SB  - IM
MH  - *COVID-19/complications
MH  - Dyspnea/epidemiology/etiology
MH  - Humans
MH  - Prospective Studies
MH  - *Pulmonary Embolism/complications/etiology
EDAT- 2022/06/02 06:00
MHDA- 2022/06/07 06:00
CRDT- 2022/06/01 11:59
PHST- 2022/06/01 11:59 [entrez]
PHST- 2022/06/02 06:00 [pubmed]
PHST- 2022/06/07 06:00 [medline]
AID - 28872 [pii]
AID - 10.26355/eurrev_202205_28872 [doi]
PST - ppublish
SO  - Eur Rev Med Pharmacol Sci. 2022 May;26(10):3751-3759. doi: 
      10.26355/eurrev_202205_28872.